A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function after Kidney Transplantation.

Datos básicos

ENSAYO CLÍNICO ALXN1210-DGF-321 2024-517568-48 HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE Año de incio: 2025

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

ALEXION PHARMACEUTICALS, INC.

Cita

Compartir